Stocks and Investing
Stocks and Investing
Wed, October 21, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Tue, October 20, 2020
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
[ 12:00 AM ] - WOPRAI
Christopher Raymond Maintained (BIIB) at Hold with Decreased Target to $265 on, Oct 20th, 2020
Christopher Raymond of Piper Sandler, Maintained "Biogen Inc." (BIIB) at Hold with Decreased Target from $270 to $265 on, Oct 20th, 2020.
Christopher has made no other calls on BIIB in the last 4 months.
There are 5 other peers that have a rating on BIIB. Out of the 5 peers that are also analyzing BIIB, 2 agree with Christopher's Rating of Hold. Following are those relevant analyst calls for the last 4 months
- Brian Abrahams of "RBC Capital" Maintained at Hold with Decreased Target to $277 on, Friday, September 18th, 2020
- Carter Gould of "Barclays" Downgraded from Buy to Hold and Decreased Target to $280 on, Monday, June 22nd, 2020
These are the ratings of the 3 analyists that currently disagree with Christopher
- Geoff Meacham of "B of A Securities" Maintained at Sell with Decreased Target to $235 on, Thursday, October 15th, 2020
- Matthew Harrison of "Morgan Stanley" Maintained at Buy with Decreased Target to $355 on, Tuesday, October 13th, 2020
- Marc Goodman of "SVB Leerink" Maintained at Buy with Decreased Target to $342 on, Wednesday, August 19th, 2020
Contributing Sources